| 51 |
23593196 | Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. | 2013 |
3 |
| 52 |
23786896 | P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. | 2013 Aug |
1 |
| 53 |
22166851 | Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. | 2012 Feb |
2 |
| 54 |
23134497 | P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil. | 2012 Nov |
2 |
| 55 |
21081657 | A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. | 2011 Feb 1 |
1 |
| 56 |
21262843 | Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. | 2011 Feb 8 |
4 |
| 57 |
21692796 | In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. | 2011 Oct |
1 |
| 58 |
22778859 | The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). | 2011 Feb 16 |
1 |
| 59 |
20010957 | Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. | 2010 Mar |
2 |
| 60 |
19250834 | Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. | 2009 Mar 15 |
1 |
| 61 |
19417029 | A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. | 2009 May 15 |
6 |
| 62 |
19631619 | Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123. | 2009 Oct 6 |
3 |
| 63 |
19910428 | A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. | 2009 Dec |
4 |
| 64 |
18678495 | Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). | 2008 Sep 1 |
1 |
| 65 |
18824002 | Several major antiepileptic drugs are substrates for human P-glycoprotein. | 2008 Dec |
1 |
| 66 |
17326793 | Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. | 2007 Mar |
2 |
| 67 |
17399990 | In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). | 2007 Jun 1 |
2 |
| 68 |
17428165 | Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. | 2007 Apr |
5 |
| 69 |
17958337 | Transport of a new erectogenic udenafil in Caco-2 cells. | 2007 Sep |
1 |
| 70 |
16952161 | Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. | 2006 Dec 1 |
1 |
| 71 |
15986399 | Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. | 2005 Aug 15 |
5 |
| 72 |
16043202 | P-glycoprotein activity and biological response. | 2005 Sep 1 |
1 |
| 73 |
14962729 | Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. | 2004 Mar |
1 |
| 74 |
15457126 | Ex vivo reversal of chemoresistance by tariquidar (XR9576). | 2004 Oct |
2 |
| 75 |
12576431 | Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. | 2003 Feb |
2 |
| 76 |
12712010 | Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. | 2003 Mar-Apr |
1 |
| 77 |
11106230 | Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. | 2000 Nov |
4 |